Quantcast

Latest Epidermal growth factor receptor Stories

2011-01-06 13:43:36

New research shows that loss of a gene called NFKBIA promotes the growth of glioblastoma multiforme, the most common and deadly form of brain cancer, and suggests that therapies that stabilize this gene may improve survival for certain glioblastoma patients. The study was published recently in the New England Journal of Medicine. "We show that NFKBIA status may be an independent predictor of survival in certain patients with glioblastoma," says senior coauthor Dr. Arnab Chakravarti, chair and...

2011-01-05 09:04:37

(Ivanhoe Newswire) -- The deletion of a gene called NFKBIA may cause glioblastoma, the most common and malignant brain cancer. Researchers at the Stanford University School of Medicine recently discovered that the deletion of this gene, which is known to promote tumor development and resistance to therapy, was present in one out of every four glioblastoma cases. When NFKBIA is deleted, certain biochemical processes occur with striking similarity to an onset of glioblastoma, which often...

2010-12-23 16:54:43

A study fast-tracked for online publication Dec. 22 in the New England Journal of Medicine has identified an important gene deletion in up to one of every four cases of glioblastoma, the most common adult brain cancer. This deletion contributes to tumor development, promotes resistance to therapy and considerably worsens a patient's survival prospects. The deletion of the gene, known as NFKBIA, triggers biochemical processes similar to those resulting from a better-known aberration common in...

4eed36960aad25c3ea887154094418b61
2010-12-23 08:02:49

Implications for blocking metastasis and improving responses to existing therapies Overexpression or hyperactivation of ErbB cell-surface receptors drives the growth of many breast cancers. Drugs, like Herceptin, that block the receptors' signals halt tumor progression in some patients. However, not all patients' tumors respond, with some becoming resistant over time. Different drugs that interfere with other steps in the signaling pathway may improve the response of patients, yet little is...

2010-12-09 07:45:00

RIDGEFIELD, Conn., Dec. 9, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs. 1.0 month for placebo) in progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients most likely to have an epidermal growth factor receptor (EGFR) mutation.(1) The updated LUX-Lung 1 data will be presented at...

2010-12-02 07:00:00

BURLINGTON, Mass., Dec. 2, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the testing rate for epidermal growth factor receptor (EGFR) mutation--a predictor of response to Genentech/Roche/OSI/Chugai's EGFR inhibitor Tarceva--in non-small-cell lung cancer (NSCLC) patients will increase by approximately 50 percent over the next 12 months, according to surveyed U.S. oncologists. In line with...

2010-11-17 13:41:47

Scientists believe they may have found a new target for treating triple negative breast cancer "“ one of the more difficult breast cancers to treat successfully and for which there is no targeted therapy at present. Triple negative breast cancer (TNBC) is a cancer that does not express receptors for oestrogen (ER), progesterone (PR) or the human epidermal growth factor (HER2). It tends to be more aggressive, occurs more often in younger women, and is difficult to treat successfully as...

2010-11-11 07:59:07

(Ivanhoe Newswire) -- Lung cancer, the most common cause of cancer-related death in men and women, is responsible for 1.3 million deaths worldwide annually.  The most common cause of lung cancer is long-term exposure to tobacco smoke, however, the occurrence of lung cancer in never-smokers accounts for as many as 15 percent of cases.  In a pilot study, different DNA alterations in the tumor genomes were found in those who smoke and never smoked, which may represent two different...

2010-11-10 06:00:00

BEIJING, Nov. 10, 2010 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that it has received approval for its real-time PCR-based Epidermal Growth Factor Receptor ("EGFR") Assay (the "EGFR PCR Assay") for the use of lung cancer targeted drugs from the State Food and Drug Administration of China (the "SFDA"). The EGFR PCR Assay is used for the detection of the...

2010-11-08 08:16:00

OMAHA, Neb., Nov. 8, 2010 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today announced completion of a development study of several new assays to detect genetic mutations using the Company's proprietary Co-amplification at Lower Denaturing Temperature PCR (COLD-PCR) technology in the Epidermal Growth Factor Receptor (EGFR) gene. EGFR mutations are found in a number of cancers, including lung and colorectal cancers. Several new targeted cancer therapeutics...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related